Here, we found that PBLD exerted anti-angiogenic effects by blocking VEGFR2 expression on HUVECs while downregulating HIF-1a-induced VEGF expression and secretion in HCC cells, which may contribute to reduce the hypoxia-induced resistance to anti-angiogenesis therapy. The gene discussed is KDR; the disease is hepatocellular carcinoma.